Caesarea, Israel, August 13, 2026
IceCure Medical Ltd., a developer of minimally invasive cryoablation technology for tumor treatment, has highlighted two new peer-reviewed publications examining the expanding role of cryoablation in breast cancer treatment. The publications discuss the potential of cryoablation as part of breast cancer treatment de-escalation, including evidence surrounding the company’s ProSense® system and clinical applications involving axillary lymph node metastases. The findings add to the growing body of clinical literature examining minimally invasive alternatives to traditional surgical tumor removal and could support continued evaluation of cryoablation in selected breast cancer patients.
Peer-Reviewed Review Examines Breast Cancer De-Escalation
The first publication, titled “Cryoablation within the Evolving Paradigm of Multidisciplinary Breast Cancer Treatment De-Escalation,” was published in Clinical Breast Cancer. The review examines available clinical evidence, procedural considerations, and the potential role of breast cryoablation within a broader shift toward less intensive cancer treatment approaches. Treatment de-escalation seeks to reduce the burden of therapy while maintaining appropriate safety and effectiveness outcomes for carefully selected patients. The review highlights the U.S. FDA marketing authorization of ProSense® for selected early-stage, low-risk breast cancers in women aged 70 and older. It also discusses updated guidance from the American Society of Breast Surgeons (ASBrS) and results from the five-year ICE3 clinical study. IceCure reported a 3.1% ipsilateral breast tumor recurrence rate in the five-year ICE3 follow-up. The company also continues to evaluate ProSense® through studies including the ChoICE post-marketing trial, adding further clinical evidence to the development of cryoablation as a breast cancer treatment option.
Cryoablation Expands to Axillary Lymph Node Disease
The second publication, titled “Cryoablation of Axillary Lymph Node Metastases for the Curative and Palliative Treatment of Breast Cancer,” was published in the Journal of Breast Imaging. The article provides practical guidance on the potential use of cryoablation for axillary lymph node metastases, broadening the clinical discussion beyond treatment of the primary breast tumor. According to the publication highlighted by IceCure, cryoablation may be considered for patients who are poor surgical candidates or decline surgery. The authors describe the procedure as having the potential for high technical success and low complication rates in appropriate settings. The publication discusses applications in both curative and palliative care, suggesting that cryoablation could have a broader role in managing regional nodal disease in selected breast cancer patients.
Advertisement
ProSense Supports Minimally Invasive Cancer Treatment
IceCure’s ProSense® system uses liquid nitrogen-based cryoablation to destroy tumors by freezing them. The company is developing and commercializing its technology as a minimally invasive alternative to surgical tumor removal, with applications across several cancer types, including breast, kidney, bone, and lung cancer. The technology is marketed in multiple regions for indications that have received applicable regulatory clearances or approvals. The two publications add to the scientific discussion surrounding minimally invasive cancer treatment and treatment de-escalation. The first review focuses on the integration of breast cryoablation into multidisciplinary care and highlights clinical evidence, regulatory authorization, and professional guidance. The second publication examines the potential application of cryoablation to axillary lymph node metastases, providing a perspective on how the technology may be used beyond the primary tumor.
For the broader MedTech and oncology community, the publications demonstrate continued interest in treatment approaches that may reduce procedural burden for appropriately selected patients. However, the findings represent published clinical evidence and expert discussion rather than a new regulatory approval announced in this release. Continued clinical research will be important in determining the appropriate patient populations, treatment settings, long-term outcomes, and role of cryoablation alongside established breast cancer therapies.
Source: IceCure Medical press release
